Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Myelodysplastic syndromes
Stage/Subtype:  childhood myelodysplastic syndromes
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 77 for your search:
Start Over
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0307, NCT00619879
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 12 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB001, UMN-2003LS055, UMN-MT2003-20, VIACELL-CB001-03, UMN-0310M3141, NCT00089596
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 60
Sponsor: Other
Protocol IDs: MT2000-09, 0001M34441, UMN-MT2000-09, UMN-2007BMT031, NCT00630253
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0208, NCT00679536
Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 60
Sponsor: NCI, Other
Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2012-0819, RP110553-P3), NCI-2013-00993, NCT01823198
AC220 With 5-Aza or Low Dose Cytarabine
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2012-1047, NCI-2013-02274, P50 CA100632, NCT01892371
NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 65
Sponsor: Other
Protocol IDs: 2012-0708, NCI-2013-02183, RP110553 05-07-04832, P01 - 5P01, NCT01904136
Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specifiec
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHSC835X2202, NCT01930162
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: AAAK8060, NCT02061800
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: BP-004, NCT02065869
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 24 and under
Sponsor: Other
Protocol IDs: SELHEM, NCI-2014-01704, NCT02212561
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, P30CA015704, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Phase: Phase II
Type: Treatment
Status: Active
Age: 45 and under
Sponsor: Other
Protocol IDs: 2005LS043, UMN-MT2005-10, UMN-0507M71475, UMN-2005LS043, UMN-BMT-MT2005-10, NCT00309842
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2001LS058, UMN-MT2001-10, 0108M06725, UMN-2001LS058, NCT00303719
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: BMT 0300 Mini, NCT00179764
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS036, UMN-MT-2005-02, UMN-0507M70121, UMN-2005LS036, NCT00305682
Combination Chemotherapy Followed By Donor Umbilical Cord Blood Transplant in Treating Infants With High-Risk Acute Leukemia or Myelodysplastic Syndromes
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 and under at diagnosis
Sponsor: Other
Protocol IDs: 2005LS075, UMN-MT2005-25, UMN-0511M77206, UMN-2005LS075, NCT00357565
Cyclophosphamide, Fludarabine, Total-Body Irradiation, and Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer or Other Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 50
Sponsor: Other
Protocol IDs: CDR0000502363, MSKCC-06014, NCT00388102
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2056.00, NCI-2010-00237, P30CA015704, P01CA018029, FHCRC-2056.00, 6171, NCT00397813
Start Over